Anzeige
Mehr »
Login
Dienstag, 14.07.2020 Börsentäglich über 12.000 News von 632 internationalen Medien
Breaking News! Ich denke, wir haben eine Aktie mit 10.000% Potential gefunden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 899527 ISIN: US0153511094 Ticker-Symbol: AXP 
Tradegate
14.07.20
13:15 Uhr
94,87 Euro
+0,52
+0,55 %
1-Jahres-Chart
ALEXION PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ALEXION PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
93,9094,5714:30
94,0194,5114:29

Aktuelle News zur ALEXION PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ALEXION PHARMACEUTICALS Aktie jetzt für 0€ handeln
SaAlexion Pharmaceuticals: Growth At A Reasonable Price (GARP)20
06.07.Alexion Pharmaceuticals Agrees to $21.5 Million Settlement With SEC in Bribery Case22
Diese Firma sitzt auf einem gewaltigen Rohstoff-Schatz im Boden! Jetzt heißt es einsteigen und anschnallen!
03.07.Alexion Pharma Agrees To Settle Charges Of FCPA Violations272WASHINGTON (dpa-AFX) - The SEC announced that Alexion Pharmaceuticals Inc. (ALXN) has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal...
► Artikel lesen
02.07.Novartis, Alexion charged with FPCA violations11
02.07.Alexion pays $21 million resolving charges of breaking U.S. foreign corruption law: SEC4
02.07.Alexion completes acquisition of Portola Pharma; SEC charges with FCPA violations14
02.07.Alexion to pay $21 million to resolve SEC charges4
02.07.ALEXION PHARMACEUTICALS, INC. - 8-K, Current Report4
02.07.SEC Charges Alexion Pharmaceuticals With FCPA Violations201Washington, D.C.--(Newsfile Corp. - July 2, 2020) - The Securities and Exchange Commission today announced that Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more...
► Artikel lesen
30.06.Alexion's European Approval And Other News: The Good, Bad And Ugly Of Biopharma12
29.06.BRIEF-Alexion Pharmaceuticals Says ULTOMIRIS Gets Marketing Authorization From European Commission11
29.06.Alexion Pharma's Ultomiris OK'd in Europe4
29.06.Alexion: EU Approves Ultomiris To Treat Atypical Hemolytic Uremic Syndrome794WASHINGTON (dpa-AFX) - Alexion Pharmaceuticals Inc. (ALXN) said that the European Commission has approved Ultomiris for the treatment of adults and children with a body weight of 10 kg or...
► Artikel lesen
25.06.Alexion's (ALXN) SC Ultomiris Meets Primary Goal in Phase III9
24.06.Alexion: Subcutaneous ULTOMIRIS Shows PK-based Non-inferiority In Phase 3 Study226WASHINGTON (dpa-AFX) - Alexion Pharmaceuticals, Inc. (ALXN) announced topline results from a Phase 3 study of weekly self-administered subcutaneous ULTOMIRIS in adults with paroxysmal nocturnal...
► Artikel lesen
24.06.BRIEF-Alexion Announces Phase 3 Study Of Weekly Subcutaneous Ultomiris Met Primary Endpoint3
12.06.AstraZeneca spinoff scores maiden FDA approval, where it will field Alexion competition and an imminent Roche rival31
12.06.Apellis counters Alexion's critique, clears up FDA questions as blockbuster decision looms23
11.06.Should You Be Tempted To 'Sell' Alexion Pharmaceuticals (ALXN) Stock28
10.06.Alexion Pharmaceuticals: Patent Resolution Is Too Little Too Late19
Seite:  Weiter >>
140 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,8